



## PharmaMar Group reviews 2016 at its annual general shareholders' meeting

**Vigo, June 29th, 2017**– PharmaMar Group is holding today its shareholders' annual general meeting where it will review 2016 and the most important milestones from this period and the growth plans of the Company will be shown, above all in the field of oncology with its molecules in different phases of clinical development.

PharmaMar closed 2016 with an 8% stock market increase while within the same period the IBEX fell 2% and the Nasdaq Biotech Index (NBI) fell 21%. Since last year's shareholders' annual general meeting, the Company's share price has increased more than 100%. During 2016, positive news was seen amongst other items with the positive results of the phase III ADMYRE study in multiple myeloma with Aplidin®, leading PharmaMar to submit the Marketing Authorization Application (MAA) to the European Medicines Agency (EMA); the recommendation from the Independent Data Monitoring Committee (IDMC) to continue with pivotal phase III, CORAIL study, with Zepsyre™ (PM1183) in platinum ovarian resistant cancer; the start of a pivotal phase II study in small cell lung cancer also with Zepsyre™; and the exclusive license, development and commercialization agreement signed with Chugai Pharmaceutical Co. Ltd. for Zepsyre™ in Japan.

As **José María Fernández, president of PharmaMar**, has explained: *"in 2016, we met our objectives and this allows us to approach our growth goal which is to have three innovative antitumoral compounds of marine origin on the market for four or five indications in the next three to four years."*

Apart from these milestones in the area of oncology, the other two companies that make up the company's biopharma sector have also a positive news flow during the year. Sylentis, presented positive results from two clinical trials with research drug SYL1001, to define the dose and assess its efficacy, respectively, in treating signs and symptoms of dry eye disease. In 2017, the Company has begun a phase III clinical trial, HELIX, for the indication of dry eye syndrome



GENOMICA, leader in the field of molecular diagnostic and genetic identification opened another line of investigation last year around the detection of non-small cell lung cancer, metastatic colon cancer and melanoma through liquid biopsy. With this process the Company launched onto the market its first kit for the detection of relevant mutations in non-small cell lung cancer: CLART® EGFR BL. This business area is added to those already existing: molecular diagnostic kits (CLART® technology) with in vitro products for oncology and infectious diseases, and analysis of human papilloma virus; genetic forensics, including genetic fingerprinting and technology transfer projects; and gene sequencing in oncology.

### **PharmaMar consolidates its support to R&D in 2016**

The company's financial position funded an increase in R&D expenditure by 30% to €78 million, focused particularly in the Oncology Business Unit, to fund ongoing clinical research of the molecules at various stages of development.

In the oncology area, €72.3 million were invested in 2016 against €55.6 million in 2015, to meet, above all, the phase III clinical trials with Zepsyre™ (PM1183) in platinum resistant ovarian cancer and small-cell lung cancer along with other preclinical studies.

*"In the near future PharmaMar will begin various clinical studies with its promising compound, Zepsyre™, in indications such as advanced endometrial cancer or BRCA 2 metastatic breast cancer where in both cases a pivotal Phase III study will be started",* states **Luis Mora, managing director of the Oncology Business Unit at PharmaMar.**

### **Sales from the PharmaMar Group continue to grow**

Net commercial sales of Yondelis® increased by 7% with respect to 2015. In addition, royalties from sales of this product by our partners, Janssen Products, LP and Taiho Pharmaceutical Co, Ltd., amounted to around \$6 million. In the Diagnostic area the sales made by GENOMICA remained stable.

In the consumer chemicals area — Zelnova Zeltia and Xylazel — the sales continued to increase rising by 3.5% during 2016.

### **About PharmaMar**

Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has an important pipeline



of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS® in Europe and has three other clinical-stage programs under development for several types of solid and hematological cancers, PM1183, plitidepsin, and PM184. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium, Austria and the United States. PharmaMar fully owns other companies: GENOMICA, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us at [www.pharmamar.com](http://www.pharmamar.com).

**Disclaimer**

This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.

**Media Contact:**

Alfonso Ortín – Communications Director [aortin@pharmamar.com](mailto:aortin@pharmamar.com) Mobile: + 34609493127  
Paula Fernández – Media Relations Manager [pfalarcon@pharmamar.com](mailto:pfalarcon@pharmamar.com) Mobile: +34 638796215  
Phone: +34 918466000



**Investor Relations:**

Phone: +34 914444500

Or please visit our website at [www.pharmamar.com](http://www.pharmamar.com)